报价延迟最少15分钟:2026/09/22 12:57 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.04 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.21/-0.45
|
|
企业价值
162.43M
|
| 资产负债 |
|
每股账面净值
0.76
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
409.66K
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia. |
